Stoliaroff-Pepin, Anna
Peine, Caroline http://orcid.org/0000-0001-6267-3452
Herath, Tim
Lachmann, Johannes
Hellenbrand, Wiebke http://orcid.org/0000-0002-8563-3629
Perriat, Delphine
Dörre, Achim http://orcid.org/0000-0001-9297-3675
Nitsche, Andreas http://orcid.org/0000-0001-8185-3176
Michel, Janine http://orcid.org/0000-0001-6227-3125
Grossegesse, Marica
Hofmann, Natalie
Rinner, Thomas
Kohl, Claudia http://orcid.org/0000-0002-1480-8911
Brinkmann, Annika http://orcid.org/0000-0002-9556-4698
Meyer, Tanja http://orcid.org/0000-0002-4631-0528
Stern, Daniel
Treindl, Fridolin
Dorner, Brigitte G. http://orcid.org/0000-0002-5100-2546
Hein, Sascha http://orcid.org/0000-0001-7257-4538
Werel, Laura http://orcid.org/0000-0003-2856-8960
Hildt, Eberhard
Gläser, Sven
Schühlen, Helmut http://orcid.org/0000-0001-8630-4264
Isner, Caroline
Peric, Alexander
Ghouzi, Ammar
Reichardt, Annette
Janneck, Matthias
Lock, Guntram
Huster, Dominik
Grünewald, Thomas http://orcid.org/0000-0002-2955-3085
Schaade, Lars
Wichmann, Ole
Harder, Thomas
Clinical trials referenced in this document:
Documents that mention this clinical trial
Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study
https://doi.org/10.1007/s15010-023-02012-z
Funding for this research was provided by:
Bundesministerium für Gesundheit
Robert Koch-Institut
Article History
Received: 20 December 2022
Accepted: 22 February 2023
First Online: 13 March 2023
Declarations
:
: S. G. received payment/honoraria from AstraZeneca, Boehringer Ingelheim, Roche Pharma, Novartis and Berlin Chemie, this had no influence on this work; all other authors reported no conflicts of interest.
: The study was approved by the Ethics Committee of the Charité Universitätsmedizin, Berlin (EA1/063/21)